DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/frbppf/cancer_generics) has announced the addition of the "Cancer Generics Market Outlook 2017" report to their offering.
The National Cancer Institute has stated that almost half of the population born today will be diagnosed with cancer at some point during their lifetime. With global cancer incidence rising to almost 13 Million in 2012 and majority of blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience prodigious growth.
According to this latest research report Cancer Generics Market Outlook 2017, this market for cancer generics is expected to grow at 13%, reaching US$ 19 Billion by 2017. The low pricing of cancer generics and increased life expectancy will be the major contributors in this growth.
The report provides an insight to the various parameters associated with Cancer Generics. It focuses on the trends and drivers instrumental in shaping the market, evaluating the role of each driver in detail and predicting its possible impact. Also covered is the segmentation of the generics market by disease types, with emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs.
The thorough study asserts that Cancer Generics is going to be the focus area for majority of players, with the market witnessing entry of a whole range of generics thereby labelling Cancer Generics as a field with enormous growth potential in the near future.
- Accord Healthcare
- Actavis Inc.
- Fresnius Kabi
- Roxane Laboratories
- Sun Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/frbppf/cancer_generics
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.